InvestorsHub Logo
Followers 534
Posts 34348
Boards Moderated 8
Alias Born 02/28/2013

Re: Junno1616 post# 309

Monday, 10/23/2023 11:29:27 AM

Monday, October 23, 2023 11:29:27 AM

Post# of 515
"Filing of the IND for TCB-008 is the next step in the clinical development of TCB-008 and aligns with our strategic refocus announced in Q2 of this year to target our clinical strategy to US trials in the future." said Bryan Kobel, Chief Executive Officer of TC BioPharm. "The IND application leverages supporting clinical study data from ongoing studies in patients with Acute Myeloid Leukemia and is also a reflection of substantial pre-clinical IND enabling work done over the course of the last 6 months by the TCB team. I would like to thank our entire team, who worked tirelessly to complete the Company's first ever US FDA trial filing. We look forward to working closely with the FDA to garner acceptance of our IND over the coming 30 days and advancing our lead candidate through clinical phases of development."

“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”


Warren Buffett

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TCBP News